McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a December 17, 2014 edition of Law360.com in an article entitled, “Many Biotech Patents At Risk After Fed. Circ. Myriad Ruling.” By striking down Myriad Genetics Inc. breast cancer test patents December 17, the Federal Circuit greatly expanded the reach of a U.S. Supreme Court decision on Myriad’s patents on human genes and has thrown into question the validity of scores of patents involving natural material, attorneys say. View the article